Is lower better? Is lowest the best?

Is lower better? Is lowest the best?

Bibliographic Details
Main Author:	Lale Tokgözoğlu
Format:	Article
Language:	English
Published:	KARE Publishing 2017-04-01
Series:	Türk Kardiyoloji Derneği Arşivi
Subjects:	ldl-cholesterol pcsk9 inhibitors cardiovascular events
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-30377

Similar Items

Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome
by: Željka Dragila, et al.
Published: (2024-02-01)

Low-density lipoprotein cholesterol lowering treatment: the current approach
by: Irina Crismaru, et al.
Published: (2020-05-01)

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
by: Jeffrey D. Browning, et al.
Published: (2010-11-01)

Low-density lipoprotein particles in atherosclerosis
by: Ya-Nan Qiao, et al.
Published: (2022-08-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
by: Markus Mohaupt
Published: (2016-07-01)

Undertreatment or Overtreatment With Statins: Where Are We?
by: Irene García-Fernández-Bravo, et al.
Published: (2022-04-01)

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
by: Jason S. Troutt, et al.
Published: (2010-02-01)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
by: Chang-Wook Nam, et al.
Published: (2019-11-01)

Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community
by: Hayato Tada, et al.
Published: (2020-11-01)

Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

<i>Acanthaster planci</i> Inhibits PCSK9 and Lowers Cholesterol Levels in Rats
by: Nurjannatul Naim Kamaruddin, et al.
Published: (2021-08-01)

Neoagarooligosaccharides enhance the level and efficiency of LDL receptor and improve cholesterol homeostasis
by: Ji Hye Yang, et al.
Published: (2017-11-01)

Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
by: Giulio Preta
Published: (2023-10-01)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
by: Mario Luca Morieri, et al.
Published: (2020-11-01)

Effect of <it>Porphyromonas gingivalis</it> infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice
by: Miyazawa Haruna, et al.
Published: (2012-09-01)

Safety of significant, long-term lipid lowering therapy. Focus on inclisiran, with Braunwald's vision
by: László Márk
Published: (2024-04-01)

The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
by: Dario Lehoux, et al.
Published: (2023-04-01)

PCSK9 - A New and Potent Approach to Lowering Cholesterol
by: Thomas F. Whayne Jr.
Published: (2013-05-01)

Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives
by: Kyung Hoon Cho, et al.
Published: (2020-09-01)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
by: Qidi Ying, et al.
Published: (2021-02-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Editorial: Genetics of Familial Hypercholesterolemia: New Insight
by: Alpo Vuorio, et al.
Published: (2021-05-01)

Advances on the treatment of Dyslipidaemias
by: Eleni Bilianou
Published: (2017-01-01)

Familial Hypercholesterolemia: Genetics, Symptoms, Diagnosis and Treatment - A Literature Overview
by: Maciej Rutkiewicz, et al.
Published: (2025-02-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a)
by: Jose A. Caparrós-Martín, et al.
Published: (2024-01-01)

Bergamot (Citrus bergamia) peel extract as new hypocholesterolemic agent modulating PCSK9 expression
by: Irene Ferrarese, et al.
Published: (2023-09-01)

Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
by: Mba CM, et al.
Published: (2019-12-01)

Gene Therapy Targeting <i>PCSK9</i>
by: Julius L. Katzmann, et al.
Published: (2022-01-01)

PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
by: Victoria Marco-Benedí, et al.
Published: (2024-09-01)

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials
by: Kusha A. Mohammadi, et al.
Published: (2023-08-01)

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
by: Angela Dardano, et al.
Published: (2021-07-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
by: Tiny Nair
Published: (2024-03-01)

<i>Acanthaster planci</i> Inhibits PCSK9 Gene Expression via Peroxisome Proliferator Response Element (PPRE) and Activation of MEK and PKC Signaling Pathways in Human Liver Cells
by: Nurjannatul Naim Kamaruddin, et al.
Published: (2022-02-01)

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
by: Tamio Teramoto, et al.
Published: (2017-06-01)

Insight into the Evolving Role of PCSK9
by: Mateusz Maligłówka, et al.
Published: (2022-03-01)

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients
by: Ulrich Julius
Published: (2018-05-01)

Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome
by: Suzan Omar Mousa, et al.
Published: (2024-07-01)

Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial
by: Hong Tan, et al.
Published: (2023-02-01)